Alimera faces NICE set back with Iluvien
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, has issued draft guidance declining to recommend Alimera's Iluvien (fluocinolone acetonide) for treating chronic diabetic macular oedema (DMO). The manufacturer's economic modelling fell short, while the firm had not submitted evidence that accurately reflected clinical practice, said the institute.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.